13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • CA224-060

    Acronym: 

    CA224-060

    ACTRN/NCT /ethics: 

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Stomach & Oesophageal
    Trial Type Treatment
    Phase Phase II Tumour Stream Gastric Cancer Gastroesophageal Junction Cancer
    Age Range 18 years and older Cancer Stage All stages
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Stomach & Oesophageal
    Trial Type Treatment
    Phase Phase II
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Gastric Cancer Gastroesophageal Junction Cancer
    Cancer Stage All stages
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A randomized, open-label, phase II clinical trial of relatatlimab 9anti-LAG-3) plus Nivolumab in combination with chemotherapy versus nivolumab in combination with chemotherapy as first-line treatment in patients with gastric or gastroesophageal junction adenocarcinoma.

    Lay Summary

    Sponsor / Cooperative group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Flinders Medical Centre Alex Scott-Hoy alex.scott-hoy@sa.gov.au 08 8204 4830 Amitesh Roy Recruiting